Bosutinib tablets are indicated for the therapy of Philadelphia chromosome-positive persistent myelogenous leukemia.
The Meals and Drug Administration has granted Alembic tentative approval for Bosutinib Tablets, 100 mg and 500 mg, which is the generic of PF Prism’s Bosulif Tablets.
Bosutinib Tablets are indicated for the therapy of a sure kind of leukemia referred to as Philadelphia chromosome-positive persistent myelogenous leukemia.
Alembic releases generic Pradaxa
Bosutinib Tablets, 100 mg and 500 mg have a market worth of roughly $ 275 million for the 12 months ending March 2024, per IQVIA.
[Read more: Alembic intros generic Perforomist]
